Zila has selected Intertrade Dental to be the exclusive distributor of its oral cancer screening product in Greece and Cyprus.
ViziLite Plus with TBlue is an FDA-approved device for the early detection of oral abnormalities that could lead to cancer.
"ViziLite Plus will provide dental professionals in Greece and Cyprus with an effective screening tool in the fight against oral cancer," said David Bethune, chairman and CEO of Zila, in a press release. "We have experience working with Intertrade and we are confident they will be a first-rate marketing partner."
Terms of the agreement were not disclosed.